Classification of usual interstitial pneumonia in patients with interstitial lung disease: Assessment of a machine learning approach using high-dimensional transcriptional data

The Lancet Respiratory Medicine

Volumn 3, Issue 6, 2015, Pages 473-482

  Kim, Su Yeon ^a   Diggans, James ^a   Pankratz, Dan ^a   Huang, Jing ^a   Pagan, Moraima ^a   Sindy, Nicole ^a   Tom, Ed ^a   Anderson, Jessica ^a   Choi, Yoonha ^a   Lynch, David A ^b   Steele, Mark P ^c   Flaherty, Kevin R ^d   Brown, Kevin K ^b   Farah, Humam ^e   Bukstein, Michael J ^e   Pardo, Annie ^f   Selman, Moisés ^g   Wolters, Paul J ^h   Nathan, Steven D ⁱ   Colby, Thomas V ^j   Myers, Jeffrey L ^d   Katzenstein, Anna Luise A ^k   Raghu, Ganesh ^l   Kennedy, Giulia C ^k   more..

^a Veracyte Inc   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e Hannibal Clinic   (United States)

^f UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^g INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ INOVA FAIRFAX HOSPITAL   (United States)

^j MAYO CLINIC   (United States)

^k SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^l UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLERGIC PNEUMONITIS; ARTICLE; BRONCHIOLITIS; CLASSIFICATION ALGORITHM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; ORGANIZING PNEUMONIA; PRIORITY JOURNAL; RNA SEQUENCE; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; BIOPSY; DIFFERENTIAL DIAGNOSIS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; LUNG; MACHINE LEARNING; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY;

BIOPSY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; LUNG; MACHINE LEARNING; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84930871576     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00140-X     Document Type: Article

References (32)

1. du Bois RM Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010, 9:129-140.
2. Hodnett PA, Naidich DP Fibrosing interstitial lung disease: a practical HRCT based approach to diagnosis and management and review of the literature. Am J Respir Crit Care Med 2013, 188:141-149.
3. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161:646-664. American Thoracic Society.
4. King TE, Pardo A, Selman M Idiopathic pulmonary fibrosis. Lancet 2011, 378:1949-1961.
5. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
6. Wells AU The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF)--practical implications. Respir Res 2013, 14(suppl 1):S2.
7. Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010, 137:129-137.
8. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184:459-466.
9. King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092.
10. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2071-2082.
11. Woodcock HV, Maher TM The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep 2014, 6:16.
12. Cottin V, Richeldi L Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. Eur Respir Rev 2014, 23:106-110.
13. Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 2008, 177:433-439.
14. Wells AU Managing diagnostic procedures in idiopathic pulmonary fibrosis. Eur Respir Rev 2013, 22:158-162.
15. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168:538-542.
16. Flaherty KR, Andrei AC, King TE, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?. Am J Respir Crit Care Med 2007, 175:1054-1060.
17. Flaherty KR, King TE, Raghu G, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. Am J Respir Crit Care Med 2004, 170:904-910.
18. Selman M, Pardo A, Barrera L, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006, 173:188-198.
19. Lockstone HE, Sanderson S, Kulakova N, et al. Gene set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis. Am J Respir Crit Care Med 2010, 181:1367-1375.
20. Katzenstein AL Smoking-related interstitial fibrosis (SRIF), pathogenesis and treatment of usual interstitial pneumonia (UIP), and transbronchial biopsy in UIP. Mod Pathol 2012, 25(suppl 1):S68-S78.
21. Pardo A, Gibson K, Cisneros J, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005, 2:e251.
22. DePianto DJ, Chandriani S, Abbas AR, et al. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax 2015, 70:48-56.
23. Selman M, Pardo A, King TE Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med 2012, 186:314-324.
24. Bauer Y, Tedrow J, de Bernard S, et al. A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2015, 52:217-231.
25. Garcia-Alvarez J, Ramirez R, Checa M, et al. Tissue inhibitor of metalloproteinase-3 is up-regulated by transforming growth factor-beta1 in vitro and expressed in fibroblastic foci in vivo in idiopathic pulmonary fibrosis. Exp Lung Res 2006, 32:201-214.
26. Yang IV, Coldren CD, Leach SM, et al. Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax 2013, 68:1114-1121.
27. Piotrowski WJ, Gorski P, Pietras T, Fendler W, Szemraj J The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis. Med Sci Monit 2011, 17:CR598-CR607.
28. Chaudhuri R, McSharry C, Brady J, et al. Low sputum MMP-9/TIMP ratio is associated with airway narrowing in smokers with asthma. Eur Respir J 2014, 44:895-904.
29. Hviid TV, Milman N, Hylenius S, Jakobsen K, Jensen MS, Larsen LG HLA-G polymorphisms and HLA-G expression in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23:30-37.
30. Li GY, Kim M, Kim JH, Lee MO, Chung JH, Lee BH Gene expression profiling in human lung fibroblast following cadmium exposure. Food Chem Toxicol 2008, 46:1131-1137.
31. Ozsolak F, Milos PM RNA sequencing: advances, challenges and opportunities. Nat Rev Genet 2011, 12:87-98.
32. Mutz KO, Heilkenbrinker A, Lonne M, Walter JG, Stahl F Transcriptome analysis using next-generation sequencing. Curr Opin Biotechnol 2013, 24:22-30.